Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on creating novel precision medicines for the treatment of rare muscle disorders. Our intimate knowledge of integrated muscle physiology at a whole-body level allows us to develop innovative solutions for patients with muscle disease where significant unmet medical need exists. By protecting and improving muscle health, our goal is to dramatically enhance the lives of people living with progressive muscle disorders.

Moving Muscle Health Forward

The path to effective therapies starts with the patient. People living with rare muscle disorders don’t let the disease define them. At Edgewise, our goal is to develop innovative therapies for progressive muscle disorders, with the same boldness and courage of the patients and families.

View stories

Protecting Muscles

Powered by our proprietary drug discovery platform, Edgewise Therapeutics is leading the development of a novel and holistic therapeutic approach to protect muscle. We directly target the muscle fibers of patients with rare muscle disorders with the aim of protecting the muscle from progressive damage. Our goal is to create healthier muscle and ultimately enhanced physical function. We are advancing our lead candidate in clinical development, with an initial focus on Duchenne, Becker and Limb-girdle muscular dystrophies, and McArdle disease.

See our science

Transforming Muscle Research

We know that for patients with rare muscle disorders, every day without an effective treatment is a day too late. We are driven by this urgency to develop novel precision medicines for severe and rare disorders.

Why we exist

Our Values

CONNECTION.png

connection

EXCELLENCE.png

excellence

COURAGE.png

courage

Latest News

Edgewise Therapeutics to Present on EDG-5506 for Becker Muscular Dystrophy at the 28th International Annual Congress of the World Muscle Society

September, 27 2023

View More
Edgewise Therapeutics to Present on EDG-5506 for Becker Muscular Dystrophy at the 28th International Annual Congress of the World Muscle Society

September, 27 2023

Edgewise Therapeutics Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker)

September, 26 2023

View More
Edgewise Therapeutics Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker)

September, 26 2023

Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction

September, 14 2023

View More
Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction

September, 14 2023

Explore all news